Novel LRRK2 inhibitors exhibit therapeutic potential for Parkinson's disease, suggesting new treatment avenues.
This patent describes novel leucine-rich repeat kinase 2 (LRRK2) inhibitors featuring a 2,4,12,13-tetrahydro-11H-5,7-(azenometheno)-dipyrazolo-[3,4-b:5',1'-g]-[1]-oxa-[4,6,8]-triazacycloundecine scaffold. These LRRK2 inhibitors exhibit therapeutic potential for the treatment of Parkinson's disease.
No takes yet. Share an insight, caveat, or question.
Song et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: